On March 3, 2026, Amphastar Pharmaceuticals entered into a supply agreement with Nanjing Letop Biotechnology for the manufacture of chemical intermediates and amended a research contract with Nanjing Hanxin, increasing costs by approximately $0.6 million. Both agreements are related party transactions and are not considered material to Amphastar's financial condition.